StockDriftsStockDriftsTop 3 Royalty Pharma Sub-Manager LLC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| CYTK | CYTOKINETICS, INC | 34.52% | 980.4K | $83.5M | +0.00%(+0) | $59.25(+23.97%) | 2026-06-30 | |
| BCAX | ZENAS BIOPHARMA, INC. | 25.05% | 2.39M | $60.6M | +0.00%(+0) | $17.28(+41.76%) | 2026-06-30 | |
| BHVN | BIOHAVEN LTD | 18.06% | 2.94M | $43.7M | +0.00%(+0) | $13.15(+8.97%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (2 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | +43.37% |
| Top 20 Holdings Unweighted | — | — | — | — | +46.47% |
Royalty Pharma Sub-Manager LLC reports $241.92M in US-listed equity holdings across 4 positions in its most recent 13F filing. Its largest disclosed positions are CYTK (34.5%), BCAX (25.1%) and BHVN (18.1%). The top 20 holdings account for 77.63% of reported assets. Its disclosed equity book has returned +43.37% cumulatively over 2 quarters. Figures reflect the Q2 2026 filing.
Sign up free to track Royalty Pharma Sub-Manager LLC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Royalty Pharma Sub-Manager LLC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 2081668). View Royalty Pharma Sub-Manager LLC’s 13F filings on SEC